BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74:242-248. [PMID: 23561229 DOI: 10.4088/jcp.12m08197] [Cited by in Crossref: 49] [Cited by in F6Publishing: 24] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Brunner V, Maynadier B, Chen L, Roques L, Hude I, Séguier S, Barthe L, Hermann P. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug Des Devel Ther 2015;9:3199-215. [PMID: 26150694 DOI: 10.2147/DDDT.S80886] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Evans VC, Alamian G, McLeod J, Woo C, Yatham LN, Lam RW. The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs 2016;30:405-17. [PMID: 27113464 DOI: 10.1007/s40263-016-0334-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evid 2015;10:49-62. [PMID: 25945081 DOI: 10.2147/CE.S54075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
4 Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat 2015;11:125-35. [PMID: 25657584 DOI: 10.2147/NDT.S54710] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
5 Sambunaris A, Gommoll C, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol 2014;29:197-205. [PMID: 24667487 DOI: 10.1097/YIC.0000000000000033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
7 Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord 2015;17. [PMID: 26644957 DOI: 10.4088/PCC.14m01753] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Chen L, Greenberg WM, Brand-Schieber E, Wangsa J, Periclou A, Ghahramani P. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Des Devel Ther 2015;9:3293-300. [PMID: 26150701 DOI: 10.2147/DDDT.S85418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
9 Montgomery SA, Gommoll CP, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr 2015;20:148-56. [PMID: 24902007 DOI: 10.1017/S1092852914000273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess 2014;3:10-9. [PMID: 27536449 DOI: 10.3109/21556660.2014.884505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
11 Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39:40-49. [PMID: 24144196 DOI: 10.1503/jpn.130040] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
12 Freeman MP, Fava M, Gommoll C, Chen C, Greenberg WM, Ruth A. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. Int Clin Psychopharmacol 2016;31:100-9. [PMID: 26584326 DOI: 10.1097/YIC.0000000000000104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
13 Renata H, Wang ZJ, Kitto RZ, Arnold FH. P450-catalyzed asymmetric cyclopropanation of electron-deficient olefins under aerobic conditions. Catal Sci Technol 2014;4:3640-3. [PMID: 25221671 DOI: 10.1039/C4CY00633J] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 6.1] [Reference Citation Analysis]
14 Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47-56. [PMID: 24172209 DOI: 10.1097/jcp.0000000000000060] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
15 Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013;33:761-771. [PMID: 23999912 DOI: 10.1007/s40261-013-0126-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
16 Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol 2016;14:191-9. [PMID: 26572745 DOI: 10.2174/1570159x14666151117122458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
17 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
18 Wang ZJ, Renata H, Peck NE, Farwell CC, Coelho PS, Arnold FH. Improved cyclopropanation activity of histidine-ligated cytochrome P450 enables the enantioselective formal synthesis of levomilnacipran. Angew Chem Int Ed Engl 2014;53:6810-3. [PMID: 24802161 DOI: 10.1002/anie.201402809] [Cited by in Crossref: 135] [Cited by in F6Publishing: 90] [Article Influence: 19.3] [Reference Citation Analysis]
19 Zimmerman M, Multach M, Walsh E, Rosenstein LK, Gazarian D, Clark HL. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs 2016;30:185-91. [PMID: 26818632 DOI: 10.1007/s40263-016-0314-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2014;29:26-35. [PMID: 24172160 DOI: 10.1097/YIC.0000000000000009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Hair P, Cameron F, Garnock-Jones KP. Levomilnacipran extended release: first global approval. Drugs 2013;73:1639-45. [PMID: 24000002 DOI: 10.1007/s40265-013-0116-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Huang Q, Zhong X, Yun Y, Yu B, Huang Y. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2016;12:2707-14. [PMID: 27822042 DOI: 10.2147/NDT.S114955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Durgam S, Chen C, Migliore R, Prakash C, Thase ME. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. Depress Anxiety 2019;36:225-34. [PMID: 30675739 DOI: 10.1002/da.22872] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]